Literature abstracts

[1]  A. Leung,et al.  The cost associated with intraperitoneal versus subcutaneous administration of erythropoietin , 1993, European Journal of Pediatrics.

[2]  R. van Leusen,et al.  Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  J. Messer,et al.  Early treatment of premature infants with recombinant human erythropoietin , 1993, Pediatrics.

[4]  R. D. Da Riol,et al.  Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. , 1992, The Journal of pediatrics.

[5]  S. Massry,et al.  Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. , 1992, Kidney international.

[6]  F. Santos,et al.  Growth hormone secretion from pituitary cells in chronic renal insufficiency. , 1992, Kidney international.

[7]  R. Vanholder,et al.  Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. , 1992, American journal of nephrology.

[8]  K. Schibler,et al.  Administration of erythropoietin to newborn rats results in diminished neutrophil production. , 1991, Blood.

[9]  R. Christensen,et al.  Effect of Erythropoietin on Granulocytopoiesis: In Vitro and in Vivo Studies in Weanling Rats , 1990, Pediatric Research.

[10]  B. Brenner,et al.  Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. , 1988, Proceedings of the National Academy of Sciences of the United States of America.